Monoclonal Antibody Therapy in Rheumatoid Arthritis: A Paradigm Shift Toward Precision Immunotherapy

Rheumatoid Arthritis (RA) is a chronic autoimmune inflammatory condition that is marked by sustained synovial inflammation, joint destruction, and extra-articular complications. While methotrexate and other conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) continue to be the first line of treatment, the majority of patients' poor response to these drugs has led to the development of monoclonal Antibody (mAb) therapies that target distinct immune mediators. This review critically examines the therapeutic development, mechanisms, clinical efficacy, and safety profiles of monoclonal Antibodies (mAbs) in the treatment of RA. A comprehensive literature search was conducted using keywords related to "rheumatoid arthritis," "biologic DMARDs," and "monoclonal antibodies" under studies published between 2010 and 2025 in the PubMed, Scopus, and Web of Science databases. Mechanistic selectivity, treatment efficacy, and tolerability were examined for major monoclonal antibodies, including TNF-α and IL-6 inhibitors, B-cell-depleting agents, and T-cell co-stimulation blockers. New biologics like bispecific antibodies, nanobodies, and antibody-drug conjugates are also reviewed in relation to precision immunotherapy. Clinical and real-world evidence proves mAb therapy significantly enhances disease remission, functional recovery, and patient-reported outcomes over csDMARDs, although infection risk and high cost are still issues. Further developments in pharmacogenomics, biomarker discovery, and biosimilars are anticipated to maximize individualized therapy and improve access. Together, mAb-based treatments represent a paradigm shift from empirical immunosuppression to precision-driven immunotherapy in RA.